Ovarian Cancer

Midwest CEPAC

ICER’s report reviews evidence on the comparative clinical effectiveness and value of poly (ADP-ribose) polymerase (PARP) inhibitors for treatment of ovarian cancer.

Interventions of Interest:

  • Rucaparib (Rubraca®, Clovis Oncology)
  • Niraparib (Zejula®, Tesaro, Inc.)
  • Olaparib (Lynparza®, AstraZeneca)

 

For questions or additional information, please contact info@icer-review.org

Associated Meetings

September 14, 2017 10AM-4PM (CT)

University of Missouri-St. Louis
Century BC Room, Millenium Student Center
1 University Boulevard
St. Louis, MO 63121

The Midwest CEPAC convened to discuss the findings of ICER's report on the comparative clinical effectiveness and value of treatment for ovarian cancer.


Key Dates

Associated Materials